Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Clinical Trial of SEEG for Drug-resistant Epilepsy (SEEG-DRE)

3. november 2026 opdateret af: Beijing Pins Medical Co., Ltd

A Clinical Trial Evaluating the Safety and Efficacy of Stereoelectroencephalography (SEEG) Electrode Combined With Radiofrequency Lesion System for the Treatment of Drug-Resistant Epilepsy

This trial evaluates the safety and efficacy of SEEG recording and functional mapping for patients with drug-resistant epilepsy. It also assesses the safety and therapeutic effectiveness of SEEG-guided radiofrequency ablation for this patient group. The study will collect clinical evidence to support the standardized application of this combined diagnostic and treatment workflow for drug-resistant epilepsy.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

Stereoelectroencephalography (SEEG) is a minimally invasive presurgical evaluation modality for epilepsy. Intracranial electrodes are implanted using stereotactic techniques to record intracranial electroencephalographic (EEG) activity and deliver direct electrical stimulation, with the aim of delineating the epileptogenic zone in patients with focal epilepsy. Based on SEEG findings, clinicians can achieve highly precise localization of the epileptogenic zone and tailored surgical planning, or directly utilize SEEG-guided radiofrequency thermocoagulation (SEEG RF-TC) as an independent therapeutic intervention.

This study adopts a single-arm target-value design with a planned enrollment of 99 patients. All enrolled participants will undergo SEEG electrode implantation, followed by continuous SEEG monitoring for EEG recording and comprehensive presurgical evaluation. Eligible patients will then receive SEEG-guided radiofrequency thermocoagulation treatment. The primary efficacy endpoints include the success rate of intracranial EEG signal recording and the therapeutic response rate of thermocoagulation.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

99

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Beijing, Kina, 100070
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100853
      • Beijing, Beijing Municipality, Kina, 100034
      • Beijing, Beijing Municipality, Kina, 100020
      • Beijing, Beijing Municipality, Kina, 100043
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina, 400037
        • Second Affiliated Hospital of Army Medical University
      • Chongqing, Chongqing Municipality, Kina, 400010
    • Fujian
      • Fuzhou, Fujian, Kina, 350004
        • First Affiliated Hospital of Fujian Medical University
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510260
        • Zhujiang Hospital of Southern Medical University
        • Kontakt:
      • Guangzhou, Guangdong, Kina, 510623
        • Guangzhou women and children's medical center
        • Kontakt:
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150086
        • The Second Affiliated Hospital of Harbin Medical University
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Kina, 430030
        • Tongji Hospital Affiliated to Tongji Medical College of HUST
        • Kontakt:
      • Wuhan, Hubei, Kina, 30014
        • Central Theater Command General Hospital of Chinese People's Liberation Army
        • Kontakt:
    • Hunan
      • Changsha, Hunan, Kina, 410028
        • Xiangya Hospital of Central South University
        • Kontakt:
    • Shandong
      • Jinan, Shandong, Kina, 250012
    • Xinjiang
      • Ürümqi, Xinjiang, Kina, 630000
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310009
        • Second Affiliated Hospital, School of Medicine, Zhejiang University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år til 70 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 2 years old and ≤ 70 years old, of any sex;
  2. Prior confirmed diagnosis of drug-resistant epilepsy (DRE);
  3. Mean epilepsy seizure frequency ≥ 1 episode per month in the 3 months preceding screening;
  4. Patients scheduled to undergo stereoelectroencephalography (SEEG) recording and RF thermocoagulation (RF-TC);
  5. The subject or their legal representative is capable of understanding the trial purpose, demonstrates sufficient adherence to the study protocol, and has provided signed informed consent;

Exclusion Criteria:

  1. Patients with contraindications to MRI;
  2. Patients with coagulation dysfunction or known coagulopathy;
  3. Women who are pregnant, planning pregnancy within 6 months, or breastfeeding;
  4. Patients with known hypersensitivity to any electrode material;
  5. Patients with contraindications to neurosurgical procedures;
  6. Subjects who have participated in any other investigational drug or medical device clinical trial within 3 months preceding screening;
  7. Subjects with severe cardiac, hepatic, or renal impairment who, in the investigator's judgment, are unsuitable for participation in this clinical investigation;
  8. Subjects who, in the investigator's judgment, demonstrate poor compliance or are unable to complete the study as required;
  9. Any other condition that, in the investigator's opinion, would render the subject unsuitable for participation.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: single arm

Participants in this trial will undergo SEEG electrode implantation followed by SEEG recording and mapping, and will complete SEEG radiofrequency thermocoagulation (RF-TC).

The patient will undergo SEEG-guided radiofrequency thermocoagulation (RF-TC). The procedure includes: electrode implantation, EEG recording, SEEG RF-TC, and electrode extraction.

Andre navne:
  • SEEG-guided radiofrequency thermocoagulation

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
SEEG Recording Success Rate
Tidsramme: Within 30 days after implantation of electrodes

The proportion of patients achieving successful SEEG recording

Within 30 days after implantation of electrodes
RF-TC Efficacy Rate
Tidsramme: Within 3 days after RF-TC

The proportion of patients achieving successful RF-TC.RF lesion measured on the post-procedural brain MRI.

Within 3 days after RF-TC

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Electrode Placement Accuracy
Tidsramme: Within 30 days after implantation of electrodes

co-registering the pre-operative surgical plan and post-op CT,calculate the error between the actual placement position of the electrode and the surgical plan at the skull entry point and the target point.Measuring unit: mm.

Within 30 days after implantation of electrodes
Technical success rate of RF-TC
Tidsramme: During RF-TC operation

Medical recording

During RF-TC operation
Vital signs-body temperature
Tidsramme: baseline, Perioperative

From medical recording

baseline, Perioperative
Vital signs-pulse
Tidsramme: baseline, Perioperative

From medical recording

baseline, Perioperative
Vital signs-respiratory rate
Tidsramme: baseline, Perioperative

From medical recording

baseline, Perioperative
Vital signs-blood pressure
Tidsramme: baseline, Perioperative

From medical recording

baseline, Perioperative
the reduction rate of spike frequency after RF-TC
Tidsramme: Periprocedural of RF-TC

SEEG recording

Periprocedural of RF-TC
Questionnaire of Device Performance Evaluation
Tidsramme: immediately after the procedure/surgery

a 5-level scale used to evaluate the Device Performance

immediately after the procedure/surgery
Seizure reduction rate
Tidsramme: 90±7 days after RF-TC

Follow up

90±7 days after RF-TC
Mini-Mental State Examination (MMSE) score
Tidsramme: Before and 90±7 days after RF-TC

Lower score indicates worse cognitive impairment

Before and 90±7 days after RF-TC
Quality of life in epilepsy-31 inventory (QOLIE-31) score
Tidsramme: Before and 90±7 days after RF-TC

For adult; Higher scores correspond to better health-related quality of life

Before and 90±7 days after RF-TC
Quality of life in epilepsy for Adolescents (QOLIE-AD-48) score
Tidsramme: Before and 90±7 days after RF-TC

For Adolescents; Higher scores correspond to better health-related quality of life

Before and 90±7 days after RF-TC
child epilepsy questionnnaire-parental form
Tidsramme: Before and 90±7 days after RF-TC

For children; Higher scores correspond to better health-related quality of life

Before and 90±7 days after RF-TC

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of adverse events and serious adverse events
Tidsramme: through study completion, an average of 5 months

Medical recording

through study completion, an average of 5 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

23. oktober 2026

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

30. september 2027

Datoer for studieregistrering

Først indsendt

21. oktober 2026

Først indsendt, der opfyldte QC-kriterier

3. november 2026

Først opslået (Faktiske)

6. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • SLXX(X)&PINS-C2-01-53

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner